Flashback and hallucinogen persisting perception disorder: Clinical aspects and pharmacological treatment approach

Israel Journal of Psychiatry and Related Sciences

Volumn 39, Issue 2, 2002, Pages 92-99

  Lerner, Arturo G ^a   Gelkopf, Marc ^b   Skladman, Irena ^a   Oyffe, Igor ^a   Finkel, Boris ^a   Sigal, Mircea ^a   Weizman, Abraham ^c,d  

^a LEV HASHARON MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c GEHA MENTAL HEALTH CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; CLONAZEPAM; CLONIDINE; DOPAMINE RECEPTOR BLOCKING AGENT; LYSERGIDE; PSYCHEDELIC AGENT;

CHEMICALLY INDUCED DISORDER; HALLUCINATION; HUMAN; REVIEW;

CLONAZEPAM; CLONIDINE; DOPAMINE ANTAGONISTS; GABA MODULATORS; HALLUCINATIONS; HALLUCINOGENS; HUMANS; LYSERGIC ACID DIETHYLAMIDE; SYMPATHOLYTICS;

EID: 0036043239     PISSN: 03337308     EISSN: 26172402     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Hofmann A. LSD: My problem child. New York: McGraw-Hill, 1980.
2. Cohen S. The hallucinogens. In: Karasu TB, editor. Treatment of psychiatric disorders. Washington DC: American Psychiatric Press, 1989.
3. Sander-Bush E, Burris KD, Knoth K. Lysergic acid diethylamide and 2,5-dimethoxy-4-mathylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. J Pharmacol Exp Ther 1988;246:924-928.
4. Young CR. Sertraline treatment of hallucinogen persisting perception disorder. J Clin Psychiatry 1997;58:85.
5. Garrat J, Alreja M, Aghajanian GK. LSD has high efficacy relative to serotonin in enhancing the cationic current Ih: Intracellular studies in rat facial motorneurons. Synapse 1993; 13:123-134.
6. Abraham HD, Aldridge AM. Adverse consequences of lysergic acid diethylamide. Addiction 1993;88:1327-1334.
7. Stahl SM. Essential psychopharmacology, neuroscientific basis and practical applications. Cambridge, UK: Cambridge University, 1996.
8. Abraham HD, Mamen A. LSD-like panic from risperidone in post-LSD visual disorder. J Clin Psychopharmacol 1996;16:238-241.
9. Abraham HD. Visual phenomenology of the LSD flashbacks. Arch Gen Psychiatry 1983; 40:884-889.
10. Sandison RA, Spencer AM, Whitelaw JDA. Therapeutic value of lysergic acid diethylamide in mental illness. J Ment Sci 1954;100:491.
11. Cooper H. Hallucinogenic drugs. Lancet 1955;268:1078-1079.
12. Elkes C, Elkes J, Mayer-Gross W. Hallucinogenic drugs. Lancet 1955,268:719.
13. Eisner B, Cohen S. Psychotherapy with lysergic acid diethylamide. J Nerv Ment Dis 1958;127:528-539.
14. Rosenthal S. Persistent hallucinosis following repeated administrations of hallucinogenic drugs. Am J Psychiatry 1964;124:238-244.
15. Robbins E, Frosch WA, Stern M. Further observations on untoward reactions to LSD. Am J Psychiatry 1967;124:393-395.
16. Horowitz MJ. Flashbacks: Recurrent intrusive images after the use of LSD. Am J Psychiatry 1969;126:565-569.
17. Schick J, Smith D. Analysis of the LSD flashback. J Psychedelic drugs 1970;3:13-19.
18. Abraham HD. A chronic impairment of color vision in users of LSD. Br J Psychiatry 1982; 140:518-520.
19. Hermle L, Spitzer M, Borchardt D, Kovar KA, Gouzoulis E. Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents? Neuropsychopharmacology 1993;8:171-176.
20. Kovar A. Chemistry and pharmacology of hallucinogens, entactogens and stimulants. Pharmacopsychiatry 1998;2:69-72.
21. Creighton FJ, Black DL, Hyde CE. Ecstasy psychosis and flashbacks. Br J Psychiatry 1991;159:713-715.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington DC: American Psychiatric Association, 1980.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third edition revised. Washington DC: American Psychiatric Association, 1987.
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington DC: American Psychiatric Association, 1994.
25. Anderson W, O'Malley J. Trifluoperazine for the trailing phenomena. JAMA 1972; 220:1244-1245.
26. Lerner AG, Gelkopf M, Oyffe I, Finkel B, Katz S, Sigal M, Weizman A. LSD-induced hallucinogen persisting perception disorder (HPPD) treatment with clonidine: An open pilot study. Int Clin Psychopharmacol 2000; 18:35-37.
27. Abraham HD, Aldridge AM, Gogia P. The psychopharmacology of hallucinogens. Neuropsychopharmacology 1996;14:285-298.
28. Miller NS. The principles and practice of addictions in psychiatry. Philadelphia, USA: W.B. Saunders Company, 1997.
29. Lerner AG, Finkel B, Oyffe I, Merenzon I, Sigal M. Clonidine treatment of hallucinogen persisting perception disorder. Am J Psychiatry 1998;155:1460.
30. Kemph JP, DeVane L, Levin GM, Jarecke R, Miller R. Treatment of aggressive children with clonidine: Results of an open pilot study. J Am Acad Child Adolesc Psychiatry 1993;32:577-581.
31. Davidson J. Drug therapy for post-traumatic stress disorder. Br J Psychiatry 1992;160: 309-314.
32. Kolb L, Burris BC, Griffiths S. Propanolol and clonidine in the treatment of post traumatic disorders of war. In: van der Kolk BA, editor. Post traumatic stress disorder: Psychological and biological sequelae. Washington DC: American Psychiatric, 1984.
33. Morehead DB. Exacerbation of hallucinogen persisting perception disorder with risperidone. J Clin Psychopharmacology 1997;17:327-328.
34. Alcantara AG. Is there a role of alpha 2 antagonism in the exacerbation of hallucinogen persisting perception disorder with risperidone? J Clin Psychopharmacology 1998;18:487-488.
35. Moskowitz D. Use of haloperidol to reduce LSD flashbacks. Milit Med 1971;136:754-756.
36. Thurlow HJ, Girvin JP. Use of antiepileptic medication in treating flashbacks from hallucinogenic drugs. Can Med Assoc 1971;105: 947-948.
37. Markel H, Lee A, Holmes RD, Domino EF. LSD flashback syndrome exacerbated by selective serotonin reuptake inhibitor antidepressants in adolescents. J Pediatr 1994;125: 817-819.
38. Lerner AG, Oyffe I, Isaacs G, Sigal M. Naltrexone treatment of hallucinogen persisting perception disorder. Am J Psychiatry 1997;154:437.